Latest news with #MedicalTechnology
Yahoo
3 days ago
- Business
- Yahoo
Intravascular lithotripsy: market competition and clinical potential: new issue of Medical Technology out now
The field of Intravascular lithotripsy (IVL), a medical procedure that uses ultrasound shockwaves to break down calcified plaque in arteries, particularly those in the coronary arteries or peripheral arteries, is generating increasing levels of interest. This month's cover feature looks at the clinical promise IVL holds beyond the financial buzz it has generated in recent times. This issue also features analyst comment on the impact Trump's tariffs are having on the medical device industry, with companies moving to stockpile equipment in certain areas. Don't miss our two interviews out of Biomed 2025, which recently took place in Tel Aviv, Israel in May, with each featuring insight into how the bioconvergence and neuromodulation markets are continuing to develop globally. All this and the latest medtech industry news, comment, and analysis from GlobalData. If you like our magazine, sign up to have each issue delivered to your inbox. "Intravascular lithotripsy: market competition and clinical potential: new issue of Medical Technology out now" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
10-05-2025
- Health
- Yahoo
MSSU launches 3D Printing Center for Precision Health
Even before completion of the Roy Blunt Health Science Innovation Center, Missouri Southern State University is test driving one of the educational opportunities that will be featured there. University officials were on hand Friday to open the new Missouri 3D Printing Center for Precision Health in Room 118 of the Ummel Technology Building in its temporary home prior to the completion of its permanent home sometime in 2026. A new initiative funded through a Science to Jobs grant provided by the Missouri Department of Higher Education and Workforce Development, it will serve as a hub for advanced research, workforce training and regional collaboration focused on the intersection of 3D printing and personalized health care. 'The Missouri 3D Printing Center for Precision Health brings new opportunities spanning into the disciplines of health care, education, research and industry,' said Crystal Lemmons, dean of the College of Health, Life Sciences and Education. 'The potential impact of this technology is unlimited in its scope, and we expect the center to continue to grow and evolve over time.' Lemmons said the center features four different kinds of 3D printers that use different materials to print realistic human organs, bones and tissue for surgeons to practice on before they cut into a real human body. 'We have the ability to make anatomical models. Some of them, depending on what the needs are, can be very lifelike,' Lemmons said. 'We have the ability to make devices or models that can be used to practice with surgery. We have the ability to make all kinds of other objects that may be needed. For example we made a tool, as kind of a practice, that helps us open some of the jugs that we have for our detergent. These are 3D printers and we have lots of different types of materials, so really the potential application for what can be made is almost limitless.' Lemmons said the center is not quite ready to bring students into its lab, but she's heard positive feedback from students about the center. 'We are searching for staff members to run the center to be able to develop our curriculum,' Lemmons said. 'As soon as that piece — we're going to work on that this coming year — is in place we anticipate a lot of student involvement. I've had some initial conversations with students, they're very excited about it, those that know about it. I've had very good student feedback so I think it's just a matter of getting the center fully launched and getting our curriculum in place.' Missouri Southern President Dean Van Galen said the center will provide unique opportunities for students to have a hands-on learning experience in 3D tech and how it is used in the medical field in a way that's not common at other universities. 'It's also important because it creates a bridge for us to work with health care providers in the region to work hand in hand in developing the use of this technology to benefit patients in our region and really across the state of Missouri,' Van Galen said. 'I think it also opens a door for more innovation and potential economic development that is centered around 3D printing in a precision lab.'
Associated Press
09-04-2025
- Business
- Associated Press
ZEISS receives FDA clearance for INTRABEAM 700
With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy. JENA, Germany, April 9, 2025 /PRNewswire/ -- As a leading provider of medical solutions in the field of neurosurgery, ZEISS Medical Technology is also dedicated to shaping modern oncology. The company recently received 510(k) clearance from the US Food and Drug Administration (FDA) for INTRABEAM® 700 – a leading-edge platform that provides robotic-assisted precision to support intraoperative radiation therapy (IORT). With its modern digital-first architecture, ZEISS INTRABEAM 700 creates SMART workflow efficiency and provides seamless connectivity, offering real added value for neurooncology and breast cancer therapy. 'Based on our established INTRABEAM platform, the newly developed ZEISS INTRABEAM 700 marks the next major step on our path to shaping the oncology workflows of tomorrow,' says Dr. Christian Schwedes, Head of the Neuro- and Spine Surgery Business Sector at ZEISS Medical Technology. 'It is especially designed for a precise, structured and risk-adapted treatment of brain tumors. From smart robotic positioning of the system, a more efficient workflow before and during the application, to bringing the system into the 21st century when it comes to digitalization and connectivity, the ZEISS INTRABEAM 700 will support the efficient and seamless collaboration between neurosurgery and oncological therapy.' Robotic-assisted Precision In oncological treatments, it must be ensured that the target area is optimally resected, and that healthy tissue is spared as much as possible. Especially during contact irradiation, it is important that the target focus always remains the same throughout the entire treatment, without interruptions or unintended movements. The cutting-edge maneuverability of the brand-new robotic ZEISS INTRABEAM SMART Stand meets these clinical requirements and offers excellent positioning control at every stage of the treatment. ZEISS INTRABEAM SMART Stand supports the precise positioning of the applicator by allowing it to approach the cavity fast, but also to slow down the speed of movement when navigating the applicator within the cavity. Once the applicator is in place, the active damping and the stand dynamics reduce residual vibrations to a minimum. 'The new incarnation of the INTRABEAM 700 really gives you more range of motion in the delivery of the applicator to the cavity. It gives you precision in how movements can be made inside of the resection cavity by the applicator,' says Christopher Cifarelli, MD Neurosurgeon, West Virginia University, USA. SMART Workflow Efficiency To achieve the best patient outcomes, healthcare professionals would like to focus solely on the treatment. ZEISS INTRABEAM 700 offers Smart Workflow Efficiency based on a digital-first architecture: The new sterile ZEISS INTRABEAM SMART Spherical Applicators come with digital-assisted applicator management and the related ZEISS INTRABEAM Spherical Sizer Set also eliminates the need for sterilization. The convenient and smart draping and balancing functions support clinical workflow efficiency further. With a single tap, all functions can be controlled with a modern and intuitive graphical user interface (GUI), familiar from other ZEISS devices. Furthermore, the completely redesigned Radiance™ treatment planning simulation software enables oncologists to assess and simulate all relevant intraoperative radiation dosage parameters based on individual patient data prior to treatment in a simpler and faster workflow, reducing unexpected treatment disruptions during surgery. This is key to successful surgical oncology procedures, resulting in optimal patient outcomes. Seamless Connectivity As part of the digitalization megatrend, connectivity is also becoming increasingly important in surgical oncology workflows worldwide. ZEISS INTRABEAM 700 can be integrated seamlessly into the surgical infrastructure and the hospital information system. Direct access to leading digital solutions from ZEISS enables faster routine workflows and simplified data management. The platform also provides integrated applicator recognition and confirmation through embedded Radio Frequency Identification (RFID) technology. For progress in medical technology The latest generation of the INTRABEAM platform highlights ZEISS' innovative strength and is an example of how the company is driving medical innovation in cancer therapy: INTRABEAM from ZEISS is currently already used in multiple large clinical studies to research intraoperative radiotherapy in brain tumors, and clinical data has already been published. In addition, work on new clinical and patient-related data in the field of breast cancer is ongoing.* ZEISS will present its latest solution for intraoperative radiotherapy from April 25 to 28, 2025, at the American Association of Neurological Surgeons Annual Scientific Meeting (AANS) in Boston, booth no. 625. Contact for investors and the press Sebastian Frericks Head of Group Finance and Investor Relations Carl Zeiss Meditec AG Phone: +49 3641 220 116 Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.
